Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,484,211

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.

Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.

What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

CONMED's (CNMD) Q4 Earnings Beat Estimates, Revenues Miss

CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.

IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.

Here's Why You Should Invest in Henry Schein (HSIC) Now

Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.

Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates

Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.

Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates

Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.

Here's Why You Should Add Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.

PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?

PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at the Diagnostics segment.

Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings

With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.

SmileDirectClub (SDC) Moves up on New Strategic Actions

SmileDirectClub's (SDC) new strategic actions are focused on supporting the key growth initiatives that will generate the highest return on investment.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.

Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates

Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.

Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings

With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.

Here's Why You Should Retain Change Healthcare (CHNG) Stock

Change Healthcare (CHNG) continues to benefit from a robust payment accuracy business. However, intense competition remains a woe.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

DaVita's (DVA) New Buyout to Enhance Transplant Experience

DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.

Should Value Investors Buy These Medical Stocks?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.